Determination of losartan in human plasma by liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS): Application to bioequivalence study

Journal of Liquid Chromatography and Related Technologies

Volumn 31, Issue 17, 2008, Pages 2643-2656

  Choi, Yoonho ^a   Kim, Jin Ki ^a   Ban, Eunmi ^a   Park, Jeong Sook ^b   Kim, Chong Kook ^a  

^a Seoul National University   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

Bioequivalence; LC ESI MS; Losartan

Indexed keywords

ACETONITRILE; ACIDS; BODY FLUIDS; CATALYST ACTIVITY; CHROMATOGRAPHIC ANALYSIS; CHROMATOGRAPHY; CURVE FITTING; DRUG PRODUCTS; FINANCIAL DATA PROCESSING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IONIZATION; IONIZATION OF LIQUIDS; MASS SPECTROMETERS; MASS SPECTROMETRY; ORGANIC ACIDS; PLASMA (HUMAN); PLASMAS; SIGNAL TO NOISE RATIO; SPECTROMETERS; SPECTROMETRY; SPECTRUM ANALYSIS;

BIOEQUIVALENCE; LC-ESI-MS; LOSARTAN;

ELECTROSPRAY IONIZATION;

LOSARTAN;

ACCURACY; ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CALIBRATION; CONTROLLED STUDY; DRUG DETERMINATION; ELECTROSPRAY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; SENSITIVITY AND SPECIFICITY;

EID: 51049092489     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826070802353189     Document Type: Article

References (13)

1. Munafo, A.; Christen, Y.; Nussberger, J.; Shum, L.Y.; Borland, R.M.; Lee, R.J.; Waeber, B.; Biollaz, J.; Brunner, H.R. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin. Pharmacol. Ther. 1992, 51, 513-521.
2. Schoenberger, J.A. Losartan with hydrochlorothiazide in the treatment of hypertension. J. Hypertens. 1995, I, S43-S47.
3. Wong, P.C.; Barnes, T.B.; Chiu, A.T.; Christ, D.D.; Duncia, J.V.; Herblin, W.F.; Timmermans, P.B.M.W.M. Losartan (DuP 753), an orally active nonpeptide angiotensin II receptor antagonist. Cardiovasc. Drug Rev. 1991, 9, 317.
4. McCarthy, K.E.; Wang, Q.; Tsai, E.W.; Gilbert, R.E.; Ip, D.P.; Brooks, M.A. Determination of losartan and its degradates in COZAAR® tablets by reversed-phase high-performance thin-layer chromatography. J. Pharm. Biomed. Anal. 1998, 17, 671-677.
5. Soldner, A.; Langgut, H.; Mutschler, E.J. HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats. J. Pharm. Biomed. Anal. 1998, 16, 863-873.
6. Jalalizadeh, H.; Souri, E.; Farsam, H.; Ansari, M. A high-performance liquid chromatographic assay for the determination of losartan in plasma. Iran. J. Pharmacol. Ther. 2003, 2, 18-21.
7. Yeung, P.F.; Jamieson, A.; Smith, G.J.; Fice, D.; Pollak, P.T. Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection. Int. J. Pharm. 2000, 204, 17-22.
8. Farthing, D.; Sica, D.; Fakhry, I.; Pedro, A.; Gehr, T.W.B. Simple high performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate. J. Chromatogr. B. 1997, 704, 374-378.
9. Tamim, J.J.I.; Salem, I.I.; Mahmood, A.S.; Zaman, Q.; Ruwayda, D. Comparative Pharmacokinetics of Two Tablet Formulations of losartan: Bioequivalence assessment. Biopharm. Drug Dispos. 2005, 26, 205-210.
10. Ritter, M.A.; Furtek, C.I.; Lo, M.W. An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J. Pharm. Biomed. Anal. 1997, 15, 1021-1029.
11. Iwasa, T.; Takano, T.; Hara, K.; Kamei, T. Method for the simultaneous determination of losartan and its major metabolite, EXP-3174, in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. J. Chromatogr. B 1999, 734, 325-330.
12. Polinko, M.; Riffel, K.; Song, H.; Lo, M.W. Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/tandem mass spectrometry. J. Pharm. Biomed. Anal. 2003, 33, 73-84.
13. Korea Food and Drug Administration, KFDA Guideline for Bioequivalence Test. 2002.